ProQR Therapeutics NV (PRQR) Shares Down 1.6%
ProQR Therapeutics NV (NASDAQ:PRQR) traded down 1.6% during trading on Thursday . The company traded as low as $5.51 and last traded at $5.51, with a volume of 84,420 shares trading hands. The stock had previously closed at $5.60.
PRQR has been the topic of several research analyst reports. Zacks Investment Research upgraded ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a report on Wednesday, August 31st. Leerink Swann reiterated a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Chardan Capital initiated coverage on ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 price objective on the stock. Finally, JMP Securities reiterated a “buy” rating on shares of ProQR Therapeutics NV in a report on Tuesday, September 6th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ProQR Therapeutics NV currently has a consensus rating of “Buy” and an average target price of $15.94.
The company has a 50-day moving average of $5.41 and a 200-day moving average of $5.04. The firm’s market capitalization is $128.87 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/proqr-therapeutics-nv-prqr-shares-down-1-6.html
ProQR Therapeutics NV (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.00. Analysts forecast that ProQR Therapeutics NV will post ($2.13) EPS for the current year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC increased its position in ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned 2.49% of ProQR Therapeutics NV worth $2,815,000 as of its most recent SEC filing. 39.21% of the stock is currently owned by institutional investors.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ProQR Therapeutics NV and related companies with MarketBeat.com’s FREE daily email newsletter.